GlobalResearch and clinical trials
Ampreloxetine for blood pressure drop on standing in MSA: main goal not met, signal in a subgroup
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The ampreloxetine trial included 73 people with MSA whose blood pressure drops when they stand up. Both trials failed to reach their main goal. In those who stopped the drug and switched to placebo, symptoms worsened. In those who continued the drug, symptoms remained stable. No rise in blood pressure while lying down was seen.
What does it mean for patients and families?
This result is preliminary information, not definitive evidence. A new confirmatory trial is needed. The drug is not yet approved.
Source
Scientific paper: Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial. Neurology, 2026. DOI: 10.1212/WNL.0000000000218284 · PubMed 42475649
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Multiple system atrophy (MSA)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.